구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | PD1/PD-L1 checkpoint inhibitor (PD1/PD-L1 checkpoint inhibitor) Peking Union Medical College Hospi…·PD-L1 31 trials |
|---|---|
Overview Program | PD1/PD-L1 checkpoint inhibitor |
Overview Company | Peking Union Medical College Hospital |
Overview Modality | CGT |
Overview Target | PD-L1 |
Overview Indication | Hepatocellular Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Advances in the study of CD47-based bispecific antibody in cancer immunotherapy.. Tumour therapy has entered the era of immunotherapy. Monoclonal antibodies (mAb), immune checkpoint inhibitors, chimeric antigen receptor T-cell (CAR-T), cytokine-induced killer (CIK), tumour-infiltrating lymphocytes (TILs) and other cellular immunotherapies have become the focus of current research. The CD47/SIRP&#x… |
Clinical Safety signal | Advances in the study of CD47-based bispecific antibody in cancer immunotherapy.. Tumour therapy has entered the era of immunotherapy. Monoclonal antibodies (mAb), immune checkpoint inhibitors, chimeric antigen receptor T-cell (CAR-T), cytokine-induced killer (CIK), tumour-infiltrating lymphocytes (TILs) and other cellular immunotherapies have become the focus of current research. The CD47/SIRP&#x… |
Clinical Selected reported efficacy | ORR 100% |
Clinical Reported ORR | 100.0% |
Clinical Result source | ClinicalTrials.gov NCT04047862 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT04047862 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | PD1/PD-L1 checkpoint inhibitor (PD1/PD-L1 checkpoint inhibitor) Peking Union Medical College Hospi…·PD-L1 31 trials |
|---|---|
Overview Program | PD1/PD-L1 checkpoint inhibitor |
Overview Company | Peking Union Medical College Hospital |
Overview Modality | CGT |
Overview Target | PD-L1 |
Overview Indication | Hepatocellular Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Advances in the study of CD47-based bispecific antibody in cancer immunotherapy.. Tumour therapy has entered the era of immunotherapy. Monoclonal antibodies (mAb), immune checkpoint inhibitors, chimeric antigen receptor T-cell (CAR-T), cytokine-induced killer (CIK), tumour-infiltrating lymphocytes (TILs) and other cellular immunotherapies have become the focus of current research. The CD47/SIRP&#x… |
Clinical Safety signal | Advances in the study of CD47-based bispecific antibody in cancer immunotherapy.. Tumour therapy has entered the era of immunotherapy. Monoclonal antibodies (mAb), immune checkpoint inhibitors, chimeric antigen receptor T-cell (CAR-T), cytokine-induced killer (CIK), tumour-infiltrating lymphocytes (TILs) and other cellular immunotherapies have become the focus of current research. The CD47/SIRP&#x… |
Clinical Selected reported efficacy | ORR 100% |
Clinical Reported ORR | 100.0% |
Clinical Result source | ClinicalTrials.gov NCT04047862 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT04047862 |
추천 비교
추천 비교